Advanced Courses

Preceptorship Courses

Apply now to join one of our Preceptorship courses!

Workshops & Courses

ESMO fosters the advancement of cancer research by supporting clinical trials workshops to inspire young oncologists from different disciplines across the globe to become the next generation of active researchers.

Patient Guides

Guides for Patients are designed to assist patients, their relatives and caregivers to better understand the nature of different types of cancer and evaluate the best available treatment choices

Personalised Medicine Explained

Video interviews and articles designed to help patients, policy makers and other non-medical professionals better understand the principles of personalised cancer medicine

Getting the Most out of Your Oncologist

Now available in Romanian, our Guide for Patients with Advanced Cancer is designed for patients, their family members and oncologists.

Designated Centres of Integrated Oncology and Palliative Care

The ESMO Designated Centres of Integrated Oncology and Palliative Care accreditation programme recognises cancer centres which provide comprehensive services in supportive and palliative care as part of their routine care.

EFPIA Disclosure Code

Policy News

Welcome to OncologyPRO, the home of ESMO’s educational and scientific resources, with Guidelines, a comprehensive list of E-Learning modules, Factsheets on biomarkers, slides and webcasts from our educational programme, and more... to support continuing medical education and daily practice!

Transparency in Drug Regulation

Publication of assessment reports in Europe and Australia makes information on medicines more easily available

In a
joint article published by Drug Discovery Today, the European Medicines Agency (EMA) and the Therapeutic Goods Administration (TGA) in Australia describe their positive experiences with the publication of assessment reports for medicines – known as European public assessment reports (EPARs) in Europe and Australian Public Assessment Reports (AusPARs) in Australia. According to the authors, increasing web traffic highlights the regulators’ success in facilitating access to medicines’ information and the rationale for medicines’ approval.

By focusing on validated, evidence-based, and up-to-date information, EPARs and AusPARs contribute to the dissemination of reliable facts on medicines and how they are evaluated and ensure transparency. The reports build on close and consistent interaction with a wide range of stakeholders in order to reflect the perspectives of different audiences.

Scientific progress and stakeholders’ desire for greater information entail a continuous evolution in the communication of information on medicines. Both regulators extensively collect feedback on the value of the published information to assess continuously how to best communicate high-quality information on medicines to users and researchers.